The latest conference call transcript from ClearPoint Neuro, Inc. reveals a promising outlook for the company's future growth and development. As announced by Joe Burnett, Chief Executive Officer, ...
[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...
2026 guidance is $52–56 million, but management excluded potential commercial revenue from certain rare‑disease partners after recent FDA guidance and also tempered expected European contribution ...
Greetings. Welcome to ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2024 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the ...
Detailed price information for Clearpoint Neuro Inc (CLPT-Q) from The Globe and Mail including charting and trades.
SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results